*:not(:first-child){margin-top:10.625rem;margin-bottom:10.625rem}.b-au_s div[id=elpais_gpt-MPU2]{position:sticky;top:3.4375rem}.b-au_s .w-lmd{width:100%;margin:0}}@media (min-width: 62.5625em)and (min-width: 62.5625em)and (max-width: 74.9175em){._g-lg-none{display:block}}@media (min-width: 62.5625em)and (max-width: 74.9175em){.tpl-h .cg .cs_m a{padding:.9375rem .25rem}}@media (min-width: 74.9375em){._g-o{max-width:74.9375rem}.tpl-h .cg .cs_m{padding:0 2rem}.b-au_b,.b-au_f{grid-column:1/9}.b-au_s{grid-column:10/13}}@media (min-width: 1310px){.x-f .x_w,.tpl-noads .x .x_w{padding-left:3.4375rem;padding-right:3.4375rem}}@media (max-width: 35.98em){._g-xs-none{display:block}.cg_f time .x_e_s:last-child{display:none}.b-au_o .c_m_c{margin-left:var(--grid-offset-justify);margin-right:var(--grid-offset-justify)}.b-au_o .c_a{margin-top:1.25rem}.b-au_b .c{grid-column-gap:0}.b-au_b .c:not(.c--p-n) .c_e{margin-left:calc(var(--grid-offset-justify)/2)}.b-au_b .c_a{margin-bottom:.5625rem}.b-au_b .c_m{padding-right:.6875rem}}@media (max-width: 47.98em){.btn-xs{padding:.125rem .5rem .0625rem}.x .btn-u{border-radius:100%;width:2rem;height:2rem}.x-nf.x-p .ep_l{grid-column:2/4}.x-nf.x-p .x_u{grid-column:4/5}.tpl-h-el-pais .btn-xpr{display:inline-flex}.tpl-h-el-pais .btn-xpr+a{display:none}.tpl-h-el-pais .x-nf.x-p .x_ep{display:flex}.tpl-h-el-pais .x-nf.x-p .x_u .btn-2{display:inline-flex}.tpl-ad-bd{margin-left:.625rem;margin-right:.625rem}.tpl-ad-bd .ad-nstd-bd{height:3.125rem;background:#fff}.tpl-ad-bd ._g-o{padding-left:.625rem;padding-right:.625rem}.b_chi .c-d:first-of-type .c_kg{order:5;margin-bottom:.25rem}.b_chi .c-d:first-of-type .c_h{order:10}.b_chi .c-d:first-of-type .c_m{order:15}.b_chi .c-d:first-of-type .c_a,.b_chi .c-d:first-of-type .c_d,.b_chi .c-d:first-of-type .c_ap,.b_chi .c-d:first-of-type .c_l,.b_chi .c-d:first-of-type .c_r{order:20}}@media (max-width: 62.5425em){.b.b_ep .b_h_w:before{content:"";width:1rem;height:2.1875rem;position:absolute;pointer-events:none;right:-1rem;bottom:0;background-image:linear-gradient(90deg,#fff,transparent);z-index:1}.z-he .b.b_ep .b_h_w:before{background-image:linear-gradient(90deg,#f2f2f2,transparent)}.b--o+.z_hr{display:none}.b-au .c_d{margin-top:0}.b-au_o .c:last-of-type{padding-bottom:1.875rem;margin-bottom:1.875rem}}
Ir al contenido_
_
La empresa estadounidense líder en el campo prepara trasplantes de médula ósea basados en la clonación humana
Los científicos de la firma ACT demuestran que los tejidos clónicos eluden el rechazo
El implante no sufre rechazo inmunológico y es capaz de realizar funciones renales
_
Recibe la mejor información en tu bandeja de entrada
Apúntate_